Clinical Trial Update: Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for APN201 (liposomal recombinant human Cu/Zn-superoxide dismutase) evaluating prevention of radiation-induced dermatitis in women with br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Radiation-induced Dermatitis

Drugs mentioned

• APN201 (liposomal recombinant human Cu/Zn-superoxide dismutase)

Snippet

Sponsor: Apeiron Biologics | Conditions: Radiation Induced Dermatitis | Phase 1, Phase 2 | Status: COMPLETED